Small E J
University of California, San Francisco, Mount Zion Cancer Center 94115, USA.
Curr Opin Oncol. 1998 May;10(3):244-52. doi: 10.1097/00001622-199805000-00012.
Our understanding of the causes of prostate cancer and improvements in screening methodologies and risk assessment prior to definitive local therapy continue to be refined. The utility of hormone therapy has been further evaluated, both as adjuvant and neoadjuvant therapy with radiation therapy or radical prostatectomy, as well as for patients with more advanced disease. Finally, modest inroads continue to be made in the treatment and understanding of hormone-refractory prostate cancer.
